Moloney Securities Asset Management LLC Acquires 56,100 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL)

Moloney Securities Asset Management LLC lifted its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTIL) by 177.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 87,799 shares of the company’s stock after purchasing an additional 56,100 shares during the period. Moloney Securities Asset Management LLC owned about 1.14% of Precision BioSciences worth $335,000 at the end of the most recent reporting period.

Separately, Janus Henderson Group PLC raised its position in Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock worth $6,322,000 after acquiring an additional 68,943 shares during the period. 37.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on DTIL. BMO Capital Markets raised shares of Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 target price for the company in a research report on Friday, January 10th. HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Precision BioSciences in a report on Friday, January 10th.

Insider Activity

In other Precision BioSciences news, insider J. Jefferson Smith sold 10,287 shares of the firm’s stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $4.79, for a total value of $49,274.73. Following the completion of the transaction, the insider now owns 87,440 shares in the company, valued at $418,837.60. This trade represents a 10.53 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Amoroso sold 36,838 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $4.67, for a total value of $172,033.46. Following the sale, the chief executive officer now owns 107,087 shares in the company, valued at approximately $500,096.29. This represents a 25.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have acquired a total of 8,734 shares of company stock valued at $39,946 over the last quarter. Company insiders own 4.00% of the company’s stock.

Precision BioSciences Price Performance

NASDAQ DTIL opened at $4.79 on Tuesday. The company has a quick ratio of 9.22, a current ratio of 9.22 and a debt-to-equity ratio of 0.34. The company has a market cap of $36.74 million, a PE ratio of 79.85 and a beta of 1.51. Precision BioSciences, Inc. has a 52 week low of $3.61 and a 52 week high of $19.43. The firm’s 50-day simple moving average is $5.02 and its two-hundred day simple moving average is $7.58.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.